Watchlist Price Alert

Plus Therapeutics Inc. (PSTV)

NASDAQ: PSTV · Real-Time Price · USD

0.34

0.01 (4.45%)

At close: Jun 09, 2025, 3:59 PM

4.45% (1D)

Bid	0.35
Market Cap	11.25M
Revenue (ttm)	1.28M
Net Income (ttm)	-27.12M
EPS (ttm)	-2.78
PE Ratio (ttm)	-0.12
Forward PE	-0.41
Analyst	Buy

Ask	0.35
Volume	3,745,494
Avg. Volume (20D)	13,362,949
Open	0.36
Previous Close	0.33
Day's Range	0.34 - 0.37
52-Week Range	0.24 - 2.40
Beta	0.88

About PSTV

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PSTV

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PSTV stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Plus Therapeutics has released their quartely earnings on May 30, 2025:

Revenue of $1.06M misses estimates by $51K, with -36.85% YoY decline.

EPS of -1.19 misses estimates by -0.85, with -58.67% YoY decline.

Why Price Moved

3 weeks ago

+28.16%

PLUS Therapeutics shares are trading higher. The c... Unlock content with Pro Subscription

1 month ago

-5.22%

Plus Therapeutics shares are trading lower after the company announced it received a Nasdaq non-compliance letter.

News

4 weeks ago · zacks.com

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.75 per share a year ago.

1 month ago · zacks.com

Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Plus (PSTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.

2 months ago · zacks.com

Plus (PSTV) Upgraded to Buy: Here's What You Should Know

Plus (PSTV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago · seekingalpha.com

Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript

Plus Therapeutics, Inc. (NASDAQ:PSTV ) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Company Participants Marc Hedrick - President and CEO Andrew Sims - CFO Conference Call Participants E...

3 months ago · zacks.com

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates

Plus Therapeutics (PSTV) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.70 per share a year ago.

3 months ago · zacks.com

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug

The FDA conditionally accepts Plus Therapeutics' new proprietary name, Reyobiq, for its lead therapeutic candidate. Stock shoots up.

3 months ago · accessnewswire.com

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement

HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with...